BUSINESS DESCRIPTION (Narrative) (Details)				3 Months Ended
	Apr. 20, 2018 USD ($)	Feb. 09, 2018 USD ($)	Jun. 29, 2017	Mar. 31, 2018 USD ($)	Mar. 31, 2017 USD ($)
Business Acquisition [Line Items]
Accumulated Net Income (Loss)				$ (2,400,000)
Working deficiency				(7,500,000)
Net cash used in operating activities				(1,145,000)	$ (326,000)
Proceeds from issuance of common stock				$ 618,000
Securities Purchase Agreement [Member] | Subsequent Events | Senior Secured Convertible Promissory Notes [Member]
Business Acquisition [Line Items]
Debt instrument, term	1 year
Debt instrument, face amount	$ 3,296,703.30
Interest rate (as a percent)	8.00%
Common stock warrant coverage	1
Transgenomics
Business Acquisition [Line Items]
Merger transaction, effective date			Jun. 29, 2017
Merger transaction, agrement date			Oct. 12, 2016
Merger transaction, name of acquired entity			Precipio Diagnostics, LLC, a privately held Delaware limited liability company
Merger transaction, pre-reverse stock split exchange ratio			10.2502
Leviston Resources LLC [Member]
Business Acquisition [Line Items]
Equity purchase agreement		$ 8,000,000
Company stock percentage of market rate		97.25%